Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

pSb_init containing anti SARS-CoV-2_RBD sybody Sb#42 Citations (1)

Originally described in: Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain
Walter JD, Hutter CAJ, Zimmermann I, Earp JD, Egloff P, Sorgenfrei M, Hürlimann LM, Gonda I, Meier G, Remm S, Thavarasah S, Plattet P, Seeger MA BioRxiv 2020.04.16.045419 Journal

Articles Citing pSb_init containing anti SARS-CoV-2_RBD sybody Sb#42

Articles
Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance. Walter JD, Scherer M, Hutter CAJ, Garaeva AA, Zimmermann I, Wyss M, Rheinberger J, Ruedin Y, Earp JC, Egloff P, Sorgenfrei M, Hurlimann LM, Gonda I, Meier G, Remm S, Thavarasah S, van Geest G, Bruggmann R, Zimmer G, Slotboom DJ, Paulino C, Plattet P, Seeger MA. EMBO Rep. 2022 Apr 5;23(4):e54199. doi: 10.15252/embr.202154199. Epub 2022 Mar 7. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.